The multi-cancer early detection (MCED) company delivered some extremely bad news to investors in February, but the stock may ...

A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in diagnoses at later stages of the disease.

Despite efforts by test maker Grail to highlight outcomes the company considers positive, some experts are warning against using the Galleri test and others like it.

"No cancer signal detected." The blood test results popped up in my online health portal without much fanfare. A doctor would chat about them with me later, congratulating me on the "phew"-worthy ...

HealthDay News — A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it. The test, called Galleri, failed to lower the number of ...

Shares in the company lost about half their value in Friday trading after the clinical trial failed to demonstrate a statistically significant reduction in stage III and IV cancers.

By Kamal Choudhury and Mariam Sunny Feb 20 (Reuters) - Grail's shares plunged nearly 50% on Friday after the company said routine screening with its cancer blood test failed to significantly boost ...

A large, three-year clinical trial designed to demonstrate how Grail’s blood test for early cancer detection could work in a broad population has preliminary results showing reduction in late-stage ...

CHICAGO -- Hundreds of people using the test company Grail were wrongly told they might have cancer, the company said in a statement Monday. Grail said a software glitch related to their telemedicine ...

GRAIL (GRAL) stock plunges after NHS-Galleri trial miss for Galleri cancer test, which was added to the Hims & Hers (HIMS) platform earlier this month. Read more here.

A blood test that screens for more than 50 cancers is correct in 62% of cases where it thinks people may have the disease, a study has found. The Galleri test, which can be given annually and is being ...

Add Yahoo as a preferred source to see more of our stories on Google. A blood test that screens for more than 50 cancers – and which is being trialled in the NHS – is correct in 62% of cases where it ...